The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Schizophrenia: More dopamine, more D 2 receptors
Open accessAbstract
Schizophrenia is a major therapeutic challenge of modern medicine, and one of the last frontiers of brain research. The illness is defined by delusions, hallucinations, disorganized behavior, and cognitive difficulties such as memory loss. It occurs in ≈1% of the world population and usually first appears in early adulthood. Although antipsychotic medications have dramatically improved the lives of patients with schizophrenia, the causes of the illness remain unknown. Of the many contemporary theories of schizophrenia, the most enduring has been the dopamine hypothesis. As originally put by Van Rossum in 1967 (ref. 1, p. 321), “When the hypothesis of dopamine blockade by neuroleptic agents can be further substantiated, it may have fargoing consequences for the pathophysiology of schizophrenia. Overstimulation of dopamine receptors could be part of the aetiology … [emphasis added].” Indeed, this speculative sentence by Van Rossum foreshadows the title of the important work by Abi-Dargham et al . (2) in this issue of PNAS: “Increased baseline occupancy of D2 receptors by dopamine in schizophrenia.” The discovery of the antipsychotic/dopamine receptor (3, 4), now commonly known as the dopamine D2 receptor, led to repeated confirmation that it is the primary site of action for all antipsychotics (3–5), including clozapine and quetiapine (6). All these drugs have different potencies at the receptor. The potency depends on the drug's dissociation constant at D2, which, in turn, relates to the rate of release of the drug from the D2 receptor. For example, the dopamine D2 receptor releases clozapine and quetiapine more rapidly than it does any of the other antipsychotic drugs (7, 8). Given the tight correlation between the clinical potency and the D2-blocking action of the antipsychotic medications, dopamine overactivity could be the common denominator in the …
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, on a neurophysiological level, a prediction error of this nature could cause an increase in the phasic activity of midbrain dopaminergic neurons, given the role that these particular neurons are believed to play in signaling salience in general and prediction errors in particular.[62][63][64][65]”
From Schizophrenia, myelination, and delayed corollary discharges: a hypothesis (2012) · cites this paper as [64]
In the citing paper
“This scenario may be more relevant to the prediction errors we hypothesize to occur in schizophrenia patients, given that it is not clear that these particular predictions (eg, regarding the sensory consequences of self-generated actions) necessarily relate to reward conditioning.”
From Schizophrenia, myelination, and delayed corollary discharges: a hypothesis (2012) · cites this paper as [64]
In the citing paper
“dopaminergic neurons have also been found to ''increase'' their firing rates in response to unpredictable and salient stimuli that are not conditioned to reward.63,64”
From Schizophrenia, myelination, and delayed corollary discharges: a hypothesis (2012) · cites this paper as [64]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antipsychotic drug doses and neuroleptic/dopamine receptors
SEEMAN, P., LEE, T., CHAU-WONG, M., & WONG, K. (1976) · Nature · doi:10.1038/261717a0 · Cited by 1,622
Self-citationLaruelle, M., Abi-Dargham, A., van Dyck, C. H., Gil, R., D'Souza, C. D., Erdos, J., McCance, E., Rosenblatt, W., Fingado, C., Zoghbi, S. S., et al. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.17.9235 · Cited by 1,291
Breier, A., Su, T.-P., Saunders, R., Carson, R. E., Kolachana, B. S., de Bartolomeis, A., Weinberger, D. R., Weisenfeld, N., Malhotra, A. K., Eckelman, W. C., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.6.2569 · Cited by 1,154
Increased baseline occupancy of D 2 receptors by dopamine in schizophrenia
Abi-Dargham, A., Rodenhiser, J., Printz, D., Zea-Ponce, Y., Gil, R., Kegeles, L. S., Weiss, R., Cooper, T. B., Mann, J. J., Van Heertum, R. L., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.14.8104 · Cited by 1,020
Kapur, S., Zipursky, R. B., & Remington, G. J. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.2.286 · Cited by 711
Self-citationBrain receptors for antipsychotic drugs and dopamine: direct binding assays.
Seeman, P. M., Chau-Wong, M., Tedesco, J., & Wong, K. (1975) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.72.11.4376 · Cited by 702
Self-citation(1962) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.1962.tb27008.x · Cited by 594
D2 Dopamine Receptors in Neuroleptic-Naive Schizophrenic Patients
Farde, L. (1990) · Archives of General Psychiatry · doi:10.1001/archpsyc.1990.01810150013003 · Cited by 529
Location of a Major Susceptibility Locus for Familial Schizophrenia on Chromosome 1q21-q22
Brzustowicz, L. M., Hodgkinson, K. A., Chow, E. W. C., Honer, W. G., & Bassett, A. S. (2000) · Science · doi:10.1126/science.288.5466.678 · Cited by 516
Burt, D. R., Creese, I., & Snyder, S. H. (1976) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)10800-6 · Cited by 482
Research works printed but not linked: 7
- J Van Rossum Neuropsychopharmacology, Proceedings Fifth Collegium Internationale Neuropsychopharmacologicum, eds H Brill, J Cole, P Deniker, H Hippius, P B Bradley (Excerpta Medica, Amsterdam), pp. 321–329 (1967).
- D R Burt, I Creese, S H Snyder Mol Pharmacol 12, 800–812 (1976).
- Kapur S. Zipursky R. Jones C. Shammi C. S. Remington G. & Seeman P. (2000) Arch. Gen. Psychiatry in press.
- S Kapur, P Seeman J Psychiatr Neurosci 25, 161–166 (2000).
- P Seeman Neuropsychopharmacology 7, 261–284 (1992).
- A C Barton, L E Black, D R Sibley Mol Pharmacol 39, 650–658 (1991).
- M Itokawa, M Toru, K Ito, H Tsuga, K Kameyama, T Haga, T Arinami, H Hamaguchi Mol Pharmacol 49, 560–566 (1996).
Cited by
Sorted by citations
Kapur, S. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.1.13 · Cited by 2,813
Self-citationHalf a century of antipsychotics and still a central role for dopamine D2 receptors
Kapur, S., & Mamo, D. (2003) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2003.09.004 · Cited by 638
Self-citationThe Role of Genes, Stress, and Dopamine in the Development of Schizophrenia
Howes, O. D., McCutcheon, R. A., Owen, M. J., & Murray, R. M. (2016) · Biological Psychiatry · doi:10.1016/j.biopsych.2016.07.014 · Cited by 640
Kellendonk, C., Simpson, E. H., Polan, H. J., Malleret, G., Vronskaya, S., Winiger, V., Moore, H., & Kandel, E. R. (2006) · Neuron · doi:10.1016/j.neuron.2006.01.023 · Cited by 520
Frank, M. J., & O'Reilly, R. C. (2006) · Behavioral Neuroscience · doi:10.1037/0735-7044.120.3.497 · Cited by 472
A Possible Role for the Striatum in the Pathogenesis of the Cognitive Symptoms of Schizophrenia
Simpson, E. H., Kellendonk, C., & Kandel, E. (2010) · Neuron · doi:10.1016/j.neuron.2010.02.014 · Cited by 478
Leyton, M. (2002) · Neuropsychopharmacology · doi:10.1016/s0893-133x(02)00366-4 · Cited by 476
Kapur, S., & Seeman, P. (2002) · Molecular Psychiatry · doi:10.1038/sj.mp.4001093 · Cited by 459
Self-citationSofouglu, M., Herman, A. I., Robinson, C. D., & Waters, A. J. (2014) · Lincoln (University of Nebraska) · Cited by 417
Psychosis pathways converge via D2High dopamine receptors
Seeman, P. M., Schwarz, J., Chen, J., Szechtman, H., Perreault, M. L., McKnight, G. S., Roder, J., Quirion, R., Boksa, P., Srivastava, L. K., et al. (2006) · Synapse · doi:10.1002/syn.20303 · Cited by 333
Self-citationMcCutcheon, R., Beck, K., Jauhar, S., & Howes, O. D. (2018) · Schizophrenia Bulletin · doi:10.1093/schbul/sbx180 · Cited by 305
Molecular Mechanisms of Schizophrenia
Lang, U. E., Puls, I., Müller, D. J., Strutz‐Seebohm, N., & Gallinat, J. (2007) · Cellular Physiology and Biochemistry · doi:10.1159/000110430 · Cited by 282
Hippocampal modulation of sensorimotor processes
Bast, T., & Feldon, J. (2003) · Progress in Neurobiology · doi:10.1016/s0301-0082(03)00112-6 · Cited by 264
Neuroimaging Biomarkers in Schizophrenia
Kraguljac, N. V., McDonald, W. M., Widge, A. S., Rodríguez, C. I., Tohen, M. F., & Nemeroff, C. B. (2021) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2020.20030340 · Cited by 252
de la Fuente‐Sandoval, C., León-Ortíz, P., Favila, R., Stephano, S., Mamo, D. C., Ramírez‐Bermúdez, J., & Graff‐Guerrero, A. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.65 · Cited by 235
Optogenetic dissection of medial prefrontal cortex circuitry
Riga, D., Matos, M. R., Glas, A., Smit, A. B., Spijker, S., & Van den Oever, M. C. (2014) · Frontiers in Systems Neuroscience · doi:10.3389/fnsys.2014.00230 · Cited by 208
Ionotropic Glutamate Receptors & CNS Disorders
Bowie, D. (2008) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152708784083821 · Cited by 207
Sex: A Significant Risk Factor for Neurodevelopmental and Neurodegenerative Disorders
Pinares-Garcia, P., Stratikopoulos, M., Zagato, A., Loke, H., & Lee, J. (2018) · Brain Sciences · doi:10.3390/brainsci8080154 · Cited by 200
Alba-Ferrara, L. M., & de Erausquin, G. A. (2013) · Frontiers in Integrative Neuroscience · doi:10.3389/fnint.2013.00009 · Cited by 200
Molecular targets of atypical antipsychotics: From mechanism of action to clinical differences
Aringhieri, S., Carli, M., Kolachalam, S., Verdesca, V., Cini, E., Rossi, M., McCormick, P. J., Corsini, G. U., Maggio, R., & Scarselli, M. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.06.012 · Cited by 204
Cerebral cortex : principles of operation
Rolls, E. T. (2016) · doi:10.82444/warw.33712699 · Cited by 187
Changes in Extracellular Dopamine Induced by Morphine and Cocaine: Crucial Control by D2 Receptors
Rougé‐Pont, F., Usiello, A., Benoit‐Marand, M., Gonon, F., Piazza, P. V., & Borrelli, E. (2002) · Journal of Neuroscience · doi:10.1523/jneurosci.22-08-03293.2002 · Cited by 177
Mitochondrial Oxidative Phosphorylation System (OXPHOS) Deficits in Schizophrenia
Bergman, O., & Ben‐Shachar, D. (2016) · The Canadian Journal of Psychiatry · doi:10.1177/0706743716648290 · Cited by 180
Animal models of schizophrenia: a critical review.
Marcotte, E. R., Pearson, D. M., & Srivastava, L. K. (2001) · PubMed Central · Cited by 175
Rubenstein, J. L. R. (2010) · Journal of Child Psychology and Psychiatry · doi:10.1111/j.1469-7610.2010.02307.x · Cited by 184
Evidence for Decreased DARPP-32 in the Prefrontal Cortex of Patients With Schizophrenia
Albert, K. A., Hemmings, H. C., Adamo, A. I. B., Potkin, S. G., Akbarian, S., Sandman, C. A., Cotman, C. W., Bunney, W. E., & Greengard, P. (2002) · Archives of General Psychiatry · doi:10.1001/archpsyc.59.8.705 · Cited by 166
A Dynamical Systems Hypothesis of Schizophrenia
Loh, M., Rolls, E. T., & Deco, G. (2007) · PLoS Computational Biology · doi:10.1371/journal.pcbi.0030228 · Cited by 164
Deurwaerdère, P. D., & Giovanni, G. D. (2016) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2016.03.004 · Cited by 170
Increased Caudate Dopamine D2 Receptor Availability as a Genetic Marker for Schizophrenia
Hirvonen, J., van Erp, T. G. M., Huttunen, J., Aalto, S., Någren, K., HUTTUNEN, M. O., Lönnqvist, J. K., Kaprio, J. A., Hietala, J. A., & Cannon, T. D. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.4.371 · Cited by 161
BASAL GANGLIA PATHOLOGY IN SCHIZOPHRENIA: DOPAMINE CONNECTIONS and ANOMALIES
Pérez‐Costas, E., Meléndez‐Ferro, M., & Roberts, R. C. (2010) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2010.06604.x · Cited by 149
Cortical Cholinergic Transmission and Cortical Information Processing in Schizophrenia
Sarter, M. (2005) · Schizophrenia Bulletin · doi:10.1093/schbul/sbi006 · Cited by 153
Sex Differences in Neurochemical Effects of Dopaminergic Drugs in Rat Striatum
Walker, Q. D., Ray, R., & Kuhn, C. M. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300915 · Cited by 148
Oxidative Stress and the Pathophysiology and Symptom Profile of Schizophrenia Spectrum Disorders
Murray, A., Rogers, J. C., Katshu, M. Z. U. H., Liddle, P. F., & Upthegrove, R. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.703452 · Cited by 152
Biological factors underlying sex differences in neurological disorders
Loke, H., Harley, V. R., & Lee, J. (2015) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2015.05.024 · Cited by 150
Schizophrenia, myelination, and delayed corollary discharges: a hypothesis
Whitford, T. J., Ford, J. M., Mathalon, D. H., Kubicki, M., & Shenton, M. E. (2012) · Schizophrenia Bulletin · doi:10.1093/schbul/sbq105 · Cited by 140
Modeling cognitive endophenotypes of schizophrenia in mice
Kellendonk, C., Simpson, E. H., & Kandel, E. R. (2009) · Trends in Neurosciences · doi:10.1016/j.tins.2009.02.003 · Cited by 136
Steeds, H., Carhart-Harris, R. L., & Stone, J. M. (2014) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125314557797 · Cited by 143
Mittal, V. A., Neumann, C. S., Saczawa, M. E., & Walker, E. F. (2008) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2007.23 · Cited by 132
Iizuka, Y., Sei, Y., Weinberger, D. R., & Straub, R. E. (2007) · Journal of Neuroscience · doi:10.1523/jneurosci.1689-07.2007 · Cited by 130
Mechanism of Action of Aripiprazole Predicts Clinical Efficacy and a Favourable Side-Effect Profile
Hirose, T., Uwahodo, Y., Yamada, S., Miwa, T., Kikuchi, T., Kitagawa, H., Burris, K. D., Altar, C. A., & Nabeshima, T. (2004) · Journal of Psychopharmacology · doi:10.1177/026988110401800308 · Cited by 128
Seeman, P. M., Tallerico, T., & Ko, F. (2003) · Synapse · doi:10.1002/syn.10232 · Cited by 128
Self-citationMcIntosh, A., Baig, B., Hall, J., Job, D., Whalley, H., Lymer, G., Moorhead, T. W., Owens, D. G., Miller, P., Porteous, D., et al. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.05.020 · Cited by 124
Betcheva‐Krajcir, E., Mushiroda, T., Takahashi, A., Kubo, M., Karachanak-Yankova, S., Zaharieva, I. T., Vazharova, R., Dimova, I. I., Milanova, V. K., Tolev, T., et al. (2009) · Journal of Human Genetics · doi:10.1038/jhg.2008.14 · Cited by 113
Movement abnormalities predict conversion to Axis I psychosis among prodromal adolescents.
Mittal, V. A., & Walker, E. F. (2007) · Journal of Abnormal Psychology · doi:10.1037/0021-843x.116.4.796 · Cited by 116
Folding Efficiency Is Rate-limiting in Dopamine D4 Receptor Biogenesis
Van Craenenbroeck, K., Clark, S. D., Cox, M. J., Oak, J. N., Liu, F., & Van Tol, H. H. M. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m414043200 · Cited by 107
Trust versus paranoia: abnormal response to social reward in psychotic illness
Gromann, P. M., Heslenfeld, D. J., Fett, A.-K. J., Joyce, D. W., Shergill, S. S., & A, L. K. M. (2013) · Brain · doi:10.1093/brain/awt076 · Cited by 103
Peptide hormone ghrelin enhances neuronal excitability by inhibition of Kv7/KCNQ channels
Shi, L., Bian, X., Qu, Z., Ma, Z., Zhou, Y., Wang, K., Jiang, H., & Xie, J. (2013) · Nature Communications · doi:10.1038/ncomms2439 · Cited by 103
Tenn, C., Fletcher, P., & Kapur, S. (2003) · Schizophrenia Research · doi:10.1016/s0920-9964(03)00009-4 · Cited by 109
Self-citationCognition and Reward Circuits in Schizophrenia: Synergistic, Not Separate
Robison, A. J., Thakkar, K. N., & Diwadkar, V. A. (2019) · Biological Psychiatry · doi:10.1016/j.biopsych.2019.09.021 · Cited by 104
The DRD2 gene 957C>T polymorphism is associated with Posttraumatic Stress Disorder in war veterans
Voisey, J., Swagell, C. D., Hughes, I. P., Morris, C. P., van Daal, A., Noble, E. P., Kann, B., Heslop, K., Young, R. M., & Lawford, B. R. (2008) · Depression and Anxiety · doi:10.1002/da.20517 · Cited by 100
How antipsychotics work—From receptors to reality
Kapur, S., Agid, O., Mizrahi, R., & Li, M. (2006) · NeuroRx · doi:10.1016/j.nurx.2005.12.003 · Cited by 102
Self-citationDopamine receptors in the brains of schizophrenia patients: a meta‐analysis of the findings
Kestler, L. P., Walker, E., & Vega, E. M. (2001) · Behavioural Pharmacology · doi:10.1097/00008877-200109000-00007 · Cited by 109
Comorbidities in Neurology: Is adenosine the common link?
Boison, D., & Aronica, E. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.04.031 · Cited by 97
Postmortem studies in schizophrenia
Harrison, P. J. (2000) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2000.2.4/pharrison · Cited by 95
Neurotransmitters Regulation and Food Intake: The Role of Dietary Sources in Neurotransmission
Gasmi, A., Nasreen, A., Menzel, A., Benahmed, A. G., Pivina, L. M., Noor, S., Peana, M., Chirumbolo, S., & Bjørklund, G. (2022) · Molecules · doi:10.3390/molecules28010210 · Cited by 118
Andersen, M. B., Fink‐Jensen, A., Peacock, L., Gerlach, J., Bymaster, F. P., Lundbæk, J. A., & Werge, T. M. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300151 · Cited by 93
Müller, D. J., Klempan, T., Luca, V. D., Sicard, T., Volavka, J., Czobor, P., Sheitman, B., Lindenmayer, J., Citrome, L., McEvoy, J. P., et al. (2005) · Neuroscience Letters · doi:10.1016/j.neulet.2004.12.037 · Cited by 91
Kleinman, J. E., Law, A. J., Lipska, B. K., Hyde, T. M., Ellis, J. K., Harrison, P. J., & Weinberger, D. R. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.10.032 · Cited by 89
Neuroimaging findings in treatment-resistant schizophrenia: A systematic review
Nakajima, S., Takeuchi, H., Plitman, E., Fervaha, G., Gerretsen, P., Caravaggio, F., Chung, J. K., Iwata, Y., Remington, G. J., & Graff‐Guerrero, A. (2015) · Schizophrenia Research · doi:10.1016/j.schres.2015.01.043 · Cited by 93
Wang, M., Pei, L., Fletcher, P. J., Kapur, S., Seeman, P. M., & Liu, F. (2010) · Molecular Brain · doi:10.1186/1756-6606-3-25 · Cited by 87
Self-citationLawford, B. R., Young, R. M., Swagell, C. D., Barnes, M., Burton, S. C., Ward, W. K., Heslop, K., Shadforth, S., van Daal, A., & Morris, C. P. (2004) · Schizophrenia Research · doi:10.1016/j.schres.2004.08.020 · Cited by 85
Willeit, M., & Praschak-Rieder, N. (2010) · NeuroImage · doi:10.1016/j.neuroimage.2010.04.030 · Cited by 84
Dejaegere, T., Serneels, L., Schäfer, M., Biervliet, J. V., Horré, K., Depboylu, C., Alvarez‐Fischer, D., Herreman, A., Willem, M., Haass, C., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0800507105 · Cited by 85
Neurotransmitters as Regulators of Tumor Angiogenesis and Immunity: The Role of Catecholamines
Sarkar, C., Chakroborty, D., & Basu, S. (2012) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-012-9395-7 · Cited by 82
Dopamine, cognitive biases and assessment of certainty: A neurocognitive model of delusions
Broyd, A., Balzan, R. P., Woodward, T. S., & Allen, P. (2017) · Clinical Psychology Review · doi:10.1016/j.cpr.2017.04.006 · Cited by 88
Tanaka, S. (2005) · Neuroscience · doi:10.1016/j.neuroscience.2005.08.070 · Cited by 78
Pitychoutis, P. M., Belmer, A., Moutkine, I., Adrien, J., & Maroteaux, L. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2015.126 · Cited by 75
Neural circuit dysfunction in schizophrenia: Insights from animal models
Sigurdsson, T. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2015.06.059 · Cited by 77
Shah, J. L., & MALLA, A. K. (2015) · Schizophrenia Research · doi:10.1016/j.schres.2015.01.010 · Cited by 78
Dosage-Dependent Effect of Dopamine D2 Receptor Activation on Motor Cortex Plasticity in Humans
Fresnoza, S. M., Stiksrud, E. M., Klinker, F., Liebetanz, D., Paulus, W., Kuo, M., & Nitsche, M. A. (2014) · Journal of Neuroscience · doi:10.1523/jneurosci.0832-14.2014 · Cited by 71
Catecholamines in patients with 22q11.2 deletion syndrome and the low-activity COMT polymorphism
Graf, W. D., Unis, A. S., Yates, C. M., Sulzbacher, S., Dinulos, M. B., Jack, R. M., Dugaw, K., Paddock, M. N., & Parson, W. (2001) · Neurology · doi:10.1212/wnl.57.3.410 · Cited by 70
Arco, A. D., Zhu, S., Terasmaa, A., Mohammed, A. H. S., & Fuxé, K. (2003) · Psychopharmacology · doi:10.1007/s00213-003-1578-8 · Cited by 71
Functional Connectivity of the Striatum in Schizophrenia and Psychotic Bipolar Disorder
Karcher, N. R., Rogers, B. P., & Woodward, N. D. (2019) · Biological Psychiatry: Cognitive Neuroscience and Neuroimaging · doi:10.1016/j.bpsc.2019.05.017 · Cited by 65
Aguilar‐Valles, A., Rodrigue, B., & Matta‐Camacho, E. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.00852 · Cited by 73
Li, M., Chen, Z., Deng, W., He, Z., Wang, Q., Jiang, L., Ma, X., Wang, Y., Chua, S. E., Cheung, C. C. G., et al. (2011) · Psychological Medicine · doi:10.1017/s0033291711002157 · Cited by 64
Tarumi, R., Tsugawa, S., Noda, Y., Plitman, E., Honda, S., Matsushita, K., Chavez, S., Sawada, K., Wada, M., Matsui, M., et al. (2019) · Neuropsychopharmacology · doi:10.1038/s41386-019-0589-z · Cited by 56
Shi, S., Leites, C., He, D., Schwartz, D., Moy, W., Shi, J., & Duan, J. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.535203 · Cited by 61
Deslauriers, J., Larouche, A., Sarret, P., & Grignon, S. (2013) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2013.05.006 · Cited by 63
The Relevance of Neuroactive Steroids in Schizophrenia, Depression, and Anxiety Disorders
MacKenzie, E. M., Odontiadis, J., Mellédo, J. L., Prior, T. I., & Baker, G. B. (2007) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-006-9086-0 · Cited by 61
Riccardi, P., Baldwin, R., Salomon, R. M., Anderson, S., Ansari, M. S., Li, R., Dawant, B. M., Bauernfeind, A. L., Schmidt, D. E., & KESSLER, R. M. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.03.022 · Cited by 55
Do phenothiazines possess antimicrobial and efflux inhibitory properties?
Grimsey, E. M., & Piddock, L. J. V. (2019) · FEMS Microbiology Reviews · doi:10.1093/femsre/fuz017 · Cited by 54
Motor coordination deficits in mice lacking RGS9.
Blundell, J. J., Hoang, C. V., Potts, B. W., Gold, S., & Powell, C. (2008) · Brain Research · doi:10.1016/j.brainres.2007.11.017 · Cited by 59
Willi, R., Weinmann, O., Winter, C., Klein, J., Sohr, R., Schnell, L., Yee, B. K., Feldon, J., & Schwab, M. E. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.4393-09.2010 · Cited by 52
Serotonergic approaches in the development of novel antipsychotics
Jones, C. A., & McCreary, A. C. (2008) · Neuropharmacology · doi:10.1016/j.neuropharm.2008.05.025 · Cited by 50
REVIEW: Cognitive effects of nicotine: genetic moderators
Herman, A. I., & Sofuoglu, M. (2010) · Addiction Biology · doi:10.1111/j.1369-1600.2010.00213.x · Cited by 52
Transcriptomics-based drug repositioning pipeline identifies therapeutic candidates for COVID-19
Le, B. L., Andreoletti, G., Oskotsky, T., Vallejo-Gracia, A., Rosales, R., Yu, K., Kosti, I., Leon, K. E., Bunis, D. G., Li, C., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-91625-1 · Cited by 51
Staddon, S. L., Arranz, M. J., Mancama, D. T., Perez-Nievas, F., Arrizabalaga, I., Anney, R., Buckland, P. R., Elkin, A., Osborne, S., Munro, J., et al. (2004) · Schizophrenia Research · doi:10.1016/j.schres.2004.06.011 · Cited by 49
Psychiatric Disorders in Toxoplasma Seropositive Patients--The CD8 Connection
Bhadra, R., Cobb, D., Weiss, L. M., & Khan, I. A. (2013) · Schizophrenia Bulletin · doi:10.1093/schbul/sbt006 · Cited by 47
Kotecha, S. A., & MacDonald, J. F. (2003) · International review of neurobiology · doi:10.1016/s0074-7742(03)54003-x · Cited by 47
An association study of DRD2 gene polymorphisms with schizophrenia in a Chinese Han population
Fan, H., Zhang, F., Xu, Y. J., Huang, X., Sun, G., Song, Y., Long, H., & Liu, P. (2009) · Neuroscience Letters · doi:10.1016/j.neulet.2009.11.017 · Cited by 46
Differential Repression by Freud-1/CC2D1A at a Polymorphic Site in the Dopamine-D2 Receptor Gene
Rogaeva, A., Ou, X., Jafar‐Nejad, H., Lemonde, S., & Albert, P. R. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m610038200 · Cited by 45
Prenatal exposure to ethinylestradiol elicits behavioral abnormalities in the rat
Dugard, M. L., Tremblay-Leveau, H., Mellier, D., & Caston, J. (2001) · Developmental Brain Research · doi:10.1016/s0165-3806(01)00205-x · Cited by 46
Neurotransmitters: promising immune modulators in the tumor microenvironment
Xiao, L., Li, X., Fang, C., Yu, J., & Chen, T. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1118637 · Cited by 46
The four dimensions: a model for the social aetiology of psychosis
Shah, J. L., Mizrahi, R., & McKenzie, K. J. (2011) · The British Journal of Psychiatry · doi:10.1192/bjp.bp.110.090449 · Cited by 47
Kesby, J. P., Cui, X., Burne, T. H. J., & Eyles, D. W. (2013) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2013.00111 · Cited by 45
Wearne, T. A., Mirzaei, M., Franklin, J. L., Goodchild, A. K., Haynes, P. A., & Cornish, J. L. (2014) · Journal of Proteome Research · doi:10.1021/pr500719f · Cited by 41
C957T DRD2 polymorphism is associated with schizophrenia in Spanish patients
Hoenicka, J., Aragüés, M., Rodríguez–Jiménez, R., Ponce, G., Martínez, I., Rubio, G., Jiménez‐Arriero, M. Á., & Palomo, T. (2006) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2006.00874.x · Cited by 42
Corripio, I., Pérez, V., Catafau, A., Mena, E., Carrió, I., & Álvarez, E. (2006) · NeuroImage · doi:10.1016/j.neuroimage.2005.07.038 · Cited by 48
Applications of positron emission tomography in psychiatry.
Parsey, R., & Mann, J. (2003) · Seminars in nuclear medicine · doi:10.1053/snuc.2003.127302 · Cited by 41
The role of D1-D2 receptor hetero-dimerization in the mechanism of action of clozapine.
Faron-Górecka, A., Górecki, A., Kuśmider, M., Wasylewski, Z., & Dziedzicka-Wasylewska, M. (2008) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2008.05.001 · Cited by 42
Metadata
- Authors
- Seeman, P., & Kapur, S.
- Affiliations
- University of Toronto (CA)
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2000-07-05
- Volume
- 97
- Issue
- 14
- Pages
- 7673-7675
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC33999
- OpenAlex
- W2022725791
- Cited by
- 279
- References
- 22
- Citations by year
- 2026: 1 · 2025: 14 · 2024: 8 · 2023: 9 · 2022: 10 · 2021: 15 · 2020: 5 · 2019: 12 · 2018: 9 · 2017: 4 · 2016: 11 · 2015: 15 · 2014: 19 · 2013: 14 · 2012: 13
- FWCI
- 6.28
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Keywords
- schizophrenia, dopamine hypothesis, dopamine D2 receptor, receptor occupancy, antipsychotic drugs, clozapine, quetiapine, receptor dissociation constant, schizophrenia pathophysiology
- MeSH terms
- Benzamides, Dopamine, Models, Biological, Psychotic Disorders, Pyrrolidines, Schizophrenia, Receptors, Dopamine D2, Dopamine Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
